1/3 Treatment of Anxiety in Autism Spectrum Disorder

1/3 自闭症谱系障碍焦虑的治疗

基本信息

批准号：
8631972
负责人：
Jeffrey James Wood
金额：
$ 22.37万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-12-16 至 2016-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8631972
关键词：
Acquired Immunodeficiency Syndrome Address Adolescent Adverse effects Affect Aftercare Age Anxiety Anxiety Disorders Autacoids Autistic Disorder Behavior Therapy Behavioral Binding Sites Characteristics Child Childhood Cities Clinical Services Clinical Trials Cognitive Cognitive Therapy Communities Comorbidity Data Data Analyses Diagnosis Disadvantaged Distress Drug Interactions Effect Modifiers (Epidemiology)Elements Evidence based treatment Felis catus Florida Frequencies Friendships Funding Goals Impairment Individual Institution Intervention Leadership Link Literature Loneliness Maintenance Measures Mediating Mediator of activation protein Mental Health Mental disorders Monitor Outcome Parents Patients Pharmaceutical Preparations Poly(ADP-ribose) Polymerases Population Procedures Protocols documentation Public Health Publications Randomized Randomized Clinical Trials Randomized Controlled Trials Recruitment Activity Recurrence Relapse Relative (related person)Research Research Personnel Resources Schools Services Severities Site Social Functioning Specific qualifier value Structure Symptoms Syndrome Testing Training Treatment Efficacy Treatment Protocols Treatment outcome United States National Institutes of Health Universities Wood material Work Youth alcohol use disorder autism spectrum disorder base behavior observation clinically significant coping data management design experience flexibility follow-up functional outcomes improved meetings programs psychosocial public health relevance quality assurance response social symposium treatment adherence treatment effect treatment response treatment site trial comparing

项目摘要

Project Summary/Abstract Autism spectrum disorders (ASD) are common neurodevelopmental syndromes affecting 1% of U.S. children. Comorbid anxiety disorders affect 40 to 50% of children with ASD, causing substantial distress and impairment over and above that caused by ASD alone. High anxiety is associated with increased severity of ASD symptoms and social maladjustment in affected youth. Further, parents of children with ASD consider anxiety- related problems to be among the top two challenges facing their children. [Although standard practice cognitive-behavioral therapy (CBT) has been established as an efficacious and safe treatment for anxiety disorders among typically developing youth, its utility in comorbid cases with ASD remains unknown. To date, no studies have experimentally compared standard practice CBT to a cognitive-behavioral intervention that has been personalized for children with a comorbid presentation of anxiety and ASD.] This gap in the literature is of particular concern because there are no empirically-supported treatment options for youth with ASD and comorbid anxiety, and existing pharmacological interventions may have some disadvantages (e.g., limited efficacy in this population, side effects, and potential for drug x drug interactions). [Accordingly, we are proposing a randomized controlled trial to be conducted at three treatment sites to evaluate the efficacy of personalized CBT for anxiety in ASD (Behavioral Intervention for Anxiety in Children with Autism: BIACA) relative to standard practice CBT for anxiety (Coping Cat program). Over the last five years, the proposed BIACA intervention has been adapted and tailored to the characteristics and needs of high-functioning children with ASD; the Coping Cat program reflects the community standard that has been empirically supported in multiple NIH-funded trials.] In response to the NIH Roadmap Initiative, BIACA employs a modular treatment approach, allowing the intervention to be personalized to each youngster's unique needs. [Thus, the proposed research will: (1) examine the efficacy of BIACA relative to Coping Cat, which represents standard practice treatment, (2) evaluate the maintenance of treatment gains, (3) examine the impact of personalized intervention on functional outcomes such as social responsiveness, loneliness, and friendship quality, (4) test autism severity as a moderator of treatment outcome, and (5) explore other moderators and mediators of treatment outcome.] A total of 180 youth (ages 8-13 years) with ASD and co-occurring anxiety will be randomly assigned to one of the two treatment conditions. The three recruitment sites for this study are UCLA, the University of South Florida (USF), and Temple University. USF will provide data management services. Considering the rising number of children diagnosed with ASD together with the frequency and severity of comorbid anxiety, the proposed work is tailored to the unique needs of youth with ASD and will provide a timely contribution to public health efforts.

项目概要/摘要自闭症谱系障碍 (ASD) 是一种常见的神经发育综合征，影响着 1% 的美国儿童。 40% 至 50% 的 ASD 儿童患有共病焦虑症，造成严重的痛苦和损害超出了自闭症谱系障碍（ASD）单独造成的范围。高度焦虑与 ASD 严重程度增加相关受影响青少年的症状和社会适应不良。此外，患有自闭症谱系障碍 (ASD) 儿童的父母认为焦虑- 相关问题成为孩子面临的两大挑战之一。 [虽然标准做法认知行为疗法（CBT）已被确立为一种有效且安全的焦虑治疗方法尽管它在典型发育青少年中存在障碍，但其在 ASD 共病病例中的效用仍然未知。迄今为止，没有研究通过实验将标准 CBT 实践与认知行为干预进行比较。已针对患有焦虑症和自闭症谱系障碍 (ASD) 共病的儿童进行了个性化治疗。] 文献中的这一差距是特别令人担忧的是，对于患有自闭症谱系障碍（ASD）的青少年，没有经验支持的治疗方案共病焦虑，现有的药物干预措施可能有一些缺点（例如，有限的在此人群中的疗效、副作用以及药物间相互作用的可能性）。 [因此，我们提议在三个治疗地点进行随机对照试验来评估疗效针对自闭症谱系障碍 (ASD) 焦虑的个性化 CBT（自闭症儿童焦虑行为干预：BIACA）相对于治疗焦虑的标准 CBT 实践（应对猫计划）。过去五年来，拟议的 BIACA 干预措施已针对高功能儿童的特征和需求进行了调整和定制患有自闭症谱系障碍（ASD）；应对猫计划反映了已得到实证支持的社区标准多项 NIH 资助的试验。] 为了响应 NIH 路线图倡议，BIACA 采用模块化治疗方法，允许根据每个年轻人的独特需求进行个性化干预。 [因此，建议研究将：(1) 检验 BIACA 相对于 Coping Cat 的功效，这代表了标准做法治疗，(2) 评估治疗效果的维持情况，(3) 检查个性化治疗的影响对社交反应、孤独感和友谊质量等功能结果的干预，(4) 测试自闭症严重程度作为治疗结果的调节因素，以及（5）探索其他调节因素和调节因素 ] 总共 180 名患有自闭症谱系障碍 (ASD) 并同时出现焦虑症的青少年（8-13 岁）将被随机分组分配给两种治疗条件之一。本研究的三个招募地点是加州大学洛杉矶分校 (UCLA)、南佛罗里达大学（USF）和天普大学。 USF 将提供数据管理服务。考虑到被诊断患有自闭症谱系障碍 (ASD) 的儿童数量不断增加，以及自闭症谱系障碍 (ASD) 的频率和严重程度共病焦虑，拟议的工作是根据自闭症谱系障碍青少年的独特需求量身定制的，并将及时提供对公共卫生工作的贡献。